Biocon Share Price Declines by 2.26% on January 8, 2025

Biocon Limited was in focus on Wednesday. On January 8, 2025, Biocon share price opened at ₹381.00, slightly down from its previous close of ₹382.35. At 11:26 AM, the share price of Biocon was trading at ₹373.70, down by 2.26% on the NSE. As of the same time, the stock price touched its day’s low at ₹372.15.

Recent Developments

Biocon Biologics Limited, a subsidiary of Biocon Limited, celebrated its first anniversary as a fully integrated global biosimilars company. Over the past year, the company has expanded its reach to more than 120 countries, providing high-quality, affordable biologic medicines to patients worldwide. With a workforce spanning over 30 nationalities, Biocon Biologics has built a robust commercial presence in key Advanced and Emerging Markets.

This milestone highlights its commitment to improving access to life-changing treatments for patients dealing with debilitating conditions. The company has earned trust and credibility among patients, physicians, and payers by ensuring business continuity through its transition to a global enterprise, positioning itself as a reliable partner in the biosimilars space.

Q2 FY 2025 Financial Highlights

In Q2 FY 2025, Biocon’s Revenue from operations increased by 4% YoY to ₹3,590 crore, or an 8% YoY rise after adjusting for the Q2FY24 revenue from Branded Formulations, India business. The reported net loss for the quarter was ₹16 crore due to higher taxes based on the geographical split of profits and minority interest. After adjusting for exceptional items, the loss stands at ₹13 crore.

About Biocon Ltd

Biocon is involved in the business of manufacturing biotechnology products and research services.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.